Novartis Cooperating With U.S. Probe Into Marketing of Entresto Heart Drug
The Novartis AG campus in Basel, Switzerland.
Photographer: Stefan Wermuth/BloombergThis article is for subscribers only.
Novartis AG said it’s cooperating with a U.S. government probe of marketing practices surrounding heart drug Entresto, one of the medicines expected to drive sales growth for the Swiss pharmaceuticals giant.
The company received a Civil Investigation Demand from the Department of Justice on Sept. 22, seeking information from January 2016 to the present, a spokesman said by email on Thursday. The agency is probing marketing and pricing, including payments to health-care workers, Novartis said in a regulatory filing on Tuesday.